Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats

Neurogastroenterology and Motility

Volumn 20, Issue 3, 2008, Pages 253-261

  Jeyabal, P V S ^a   Kumar, R ^a   Gangula, P R R ^a   Micci, M A ^a   Pasricha, P J ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation end product; ALT 711; Aminoguanidine; Diabetes; Neuronal nitric oxide synthase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; DRINKING WATER; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DUODENUM; ENTERIC NERVOUS SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; IMMUNOHISTOCHEMISTRY; MALE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 38849150982     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01018.x     Document Type: Article

References (41)

1. Bytzer P., Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002 97 : 604 11.
2. Russo A, Fraser R, Adachi K, Horowitz M, Boeckxstaens G. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut 1999 44 : 72 6.
3. Gangula PR, Maner WL, Micci MA, Garfield RE, Pasricha PJ. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol 2007 292 : 725 33.
4. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15 000 adults. Arch Intern Med 2001 161 : 1989 96.
5. Nakao K, Takahashi T, Utsunomiya J, Owyang C. Extrinsic neural control of nitric oxide synthase expression in the myenteric plexus of rat jejunum. J Physiol 1998 507 : 549 60.
6. Martinez-Cuesta MA, Massuda H, Whittle BJ, Moncada S. Impairment of nitrergic-mediated relaxation of rat isolated duodenum by experimental diabetes. Br J Pharmacol 1995 114 : 919 24.
7. Watkins CC, Sawa A, Jaffrey S et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000 106 : 373 84.
8. He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001 121 : 427 34.
9. von der Ohe MR. Diarrhoea in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995 7 : 730 6.
10. Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993 68 : 691 702.
11. Ogbonnaya KI, Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. Arch Intern Med 1991 150 : 262 7.
12. Morbini P, Villa C, Campo I, Zorzetto M, Inqhilleris S, Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006 19 : 1437 45.
13. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006 7 : 985 91.
14. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001 44 : 129 46.
15. Korenaga K, Micci MA, Taglialatela G, Pasricha PJ. Suppression of nNOS expression in rat enteric neurons by the receptor for advanced glycation end-products. Neurogastroenterol Motil 2006 18 : 392 400.
16. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin- diabetic rats. Diabetologia 1992 35 : 946 50.
17. Liu J, Qiao X, Micci MA, Pasricha PJ, Chen JD. Improvement of gastric motility with gastric electrical stimulation in STZ-induced diabetic rats. Digestion 2004 70 : 159 66.
18. Twigg SM, Cao Z, MCLennan SV et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002 143 : 4907 15.
19. Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004 47 : 331 9.
20. Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001 50 : 2792 808.
21. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE- induced collagen production in NRK-49 F cells. J Cell Biochem 2001 81 : 102 13.
22. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997 272 : 17810 4.
23. Li JH, Wang W, Huang XR et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004 164 : 1389 97.
24. Usta MF, Bivalacqua TJ, Yang DY et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003 170 : 1437 42.
25. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003 17 : 1289 91.
26. Usta MF, Kendirci M, Gur S et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006 3 : 242 50.
27. Matsunaga N, Anan I, Forsgren S et al. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathol 2002 104 : 441 7.
28. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003 52 : 2353 62.
29. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003 419 : 31 40.
30. Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000 60 : 55 65.
31. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998 47 : 1114 20.
32. Mustafa A, Gado AM, Al-Shabanah OA, Al-Bekairi AM. Protective effect of aminoguanidine against paraquat-induced oxidative stress in the lung of mice. Comp Biochem Physiol C Toxicol Pharmacol 2002 132 : 391 7.
33. Kumari K, Umar S, Bansal V, Sahib MK. Monoaminoguanidine inhibits aldose reductase. Biochem Pharmacol 1991 41 : 1527 8.
34. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001 276 : 48967 72.
35. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001 357 : 593 615.
36. Jianmongkol S, Vuletich JL, Bender AT, Demady DR, Osawa Y. Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase. J Biol Chem 2000 275 : 13370 6.
37. Vasan S, Zhang X, Zhang X et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996 382 : 275 8.
38. Cooper ME, Thallas V, Forbes J et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000 43 : 660 4.
39. Roufail E, Soulis T, Boel E, Cooper ME, Rees S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia 1998 41 : 1419 25.
40. Shotton HR, Adams A, Lincoln J. Effect of aminoguanidine treatment on diabetes-induced changes in the myenteric plexus of rat ileum. Auton Neurosci 2007 132 : 16 26.
41. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002 1 : 1 15.